HealthDay News — Prenatal exposure to specific components of fine particulate matter (PM 2.5) and postnatal ozone exposure are associated with an increased risk for autism spectrum disorder (ASD), ...

If finalized, the rule would override state laws, including those that ban reporting of medical debt on consumer credit reports ...

The Food and Drug Administration (FDA) has designated Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht) as interchangeable biosimilars to the reference products Prolia ® (denosumab) and ...

HealthDay News — Canada may lose its measles elimination status amid a yearlong outbreak that has infected more than 5000 people and killed two infants, health officials said this week.

Rates for plans sold through federal Obamacare marketplaces will rise, on average, by 30% next year, according to a new analysis from the health research group KFF. States that run their own ...

HealthDay News — The stillbirth rate in the US from 2016 through 2022 appears to be higher than the rate reported in 2021 by the US Centers for Disease Control and Prevention, according to a research ...

HealthDay News — Exposure to the volatile organic compound tetrachloroethylene (PCE) is associated with a higher risk for significant liver fibrosis, according to a study published online October 16 ...

Specific recommendations made for adult, pediatric, neonatal life support; resuscitation education; systems of care.

The suit requests a temporary restraining order requiring the USDA to use existing contingency funds to continue payments.

Findings showed Staloral Birch, compared with placebo, demonstrated a 41% improvement in the ARC total combined score during the second pollen season. Topline data were announced from a phase 3b trial ...

The Food and Drug Administration (FDA) has designated Stoboclo ® (denosumab-bmwo) and Osenvelt ® (denosumab-bmwo) as interchangeable biosimilars to the reference products Prolia ® (denosumab) and ...

The decision came following a meeting with the FDA during which the Company and the Agency could not come to an agreement on the design of the VALOR clinical trial.